Kura Oncology, Inc. Forecast, price target & analysts
Kura Oncology, Inc. Target price 2025 - Analyst rating & recommendation
Kura Oncology, Inc. Classifications & Recommendation:
Kura Oncology, Inc. Price Target
| Target Price | $26.69 |
| Price | $5.89 |
| Potential |
353.18%
register free of charge
|
| Number of Estimates | 13 |
|
13 Analysts have issued a price target Kura Oncology, Inc. 2026 .
The average Kura Oncology, Inc. target price is $26.69.
This is
353.18%
register free of charge
$40.00
579.12%
register free of charge
$10.00
69.78%
register free of charge
|
|
| A rating was issued by 16 analysts: 13 Analysts recommend Kura Oncology, Inc. to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Kura Oncology, Inc. stock has an average upside potential 2026 of
353.18%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 53.88 | 133.98 |
| 148.66% | ||
| EBITDA Margin | -357.00% | -190.05% |
| 46.76% | ||
| Net Margin | -293.29% | -105.74% |
| 63.95% |
14 Analysts have issued a sales forecast Kura Oncology, Inc. 2025 . The average Kura Oncology, Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Kura Oncology, Inc. EBITDA forecast 2025. The average Kura Oncology, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
14 Kura Oncology, Inc. Analysts have issued a net profit forecast 2025. The average Kura Oncology, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.02 | -1.81 |
| 2.88% | 10.40% | |
| P/E | negative | |
| EV/Sales | negative |
14 Analysts have issued a Kura Oncology, Inc. forecast for earnings per share. The average Kura Oncology, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Kura Oncology, Inc....
Current Kura Oncology, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| UBS |
Locked
➜
Locked
|
Locked | Mar 06 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 27 2025 |
| Wedbush |
Locked
➜
Locked
|
Locked | Feb 06 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 06 2025 |
| JMP Securities |
Locked
➜
Locked
|
Locked | Feb 06 2025 |
| Scotiabank |
Locked
➜
Locked
|
Locked | Jan 08 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Dec 09 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
UBS:
Locked
➜
Locked
|
Mar 06 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 27 2025 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Feb 06 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 06 2025 |
|
Locked
JMP Securities:
Locked
➜
Locked
|
Feb 06 2025 |
|
Locked
Scotiabank:
Locked
➜
Locked
|
Jan 08 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Dec 09 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
